Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


NIH Funds Study of Fully Personalized Immunotherapy AGS-004 Combined With a Latency Reversing Therapy for the Treatment of HIV 

 

NIH Funds Study of Fully Personalized Immunotherapy AGS-004 Combined With a Latency Reversing Therapy for the Treatment of HIV
April 1, 2015 – (Argos) – Argos Therapeutics, Inc. (Nasdaq:ARGS), today announced that the NIH Division of AIDS has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.

 

 

Posted on 1-Apr-15 by Berry, Cassie
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: